Heart-Safe chemo? new study tests vasodilators to prevent chest pain in cancer patients
NCT ID NCT07456852
First seen Mar 14, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This phase I/II trial tests whether vasodilator drugs (isosorbide mononitrate or diltiazem) can prevent blood vessel damage caused by fluoropyrimidine chemotherapy in 60 patients with gastrointestinal cancer. Researchers will monitor blood vessel reactivity using a non-invasive device called EndoPAT. The goal is to reduce chest pain and heart risks during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT DIGESTIVE SYSTEM NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isosorbide mononitrate, diltiazem, or placebo
What this could lead to
If it works, this could point toward a way to prevent chemotherapy-related blood vessel damage and chest pain, making cancer treatment safer.
What could go wrong
This is an early-phase pilot study with only 60 participants, so results may not apply broadly. The vasodilator drugs themselves can cause side effects like low blood pressure or dizziness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.